Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T15:42:05.291Z.
Calculation as of: 2026-10-06T15:42:05.291Z.
Quote observation: 2026-10-06T15:38:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bcc3f1894ec499320e43c54a24f2662d6ad9e54feca4b92c79248349e67b8166
EARNINGS YIELD
N/A
Market Cap
$4.12M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.05M
Earnings Yield
N/A
TTM Avg
120.37%
3Y Avg
120.37%
5Y Avg
120.37%
Market Cap
$4.33M
Earnings Yield
N/A
TTM Avg
1.27%
3Y Avg
1.27%
5Y Avg
1.27%
Market Cap
$4.40M
Earnings Yield
N/A
TTM Avg
106.12%
3Y Avg
106.12%
5Y Avg
106.12%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRI Bio, Inc. (GRI) | $4.17M | N/A | N/A | N/A | N/A |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.12M | N/A | N/A | N/A | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.20M | N/A | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.05M | N/A | 120.37% | 120.37% | 120.37% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.08M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.33M | N/A | 1.27% | 1.27% | 1.27% |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.40M | N/A | 106.12% | 106.12% | 106.12% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | N/A | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.69M | N/A | N/A | N/A | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.55M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
